Health and Pharma

12/26/2025

Researchers at Mass General Brigham engineered a retargeted HSV-1 virus that selectively infects cells, delivers five immunomodulators, and avoids healthy tissue. A single intratumoral dose increased , natural killer, and myeloid responses, reduced T-cell exhaustion, enabled PET tracking, and significantly prolonged survival, highlighting a multipronged strategy for treatment.
https://healthandpharma.net/glioblastoma-oncolytic-virus-immunity-brain-cancer

12/26/2025

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a TRBC2-targeted -drug conjugate ( ) for T-cell and , addressing half of patients previously lacking precision options. The therapy selectively eradicated TRBC2+ , preserved immune-critical , and achieved durable 150-day clearance in preclinical models with minimal toxicity.
https://healthandpharma.net/adc-trbc2-antibody-tcell-cancer-lymphomas-leukemias

12/20/2025

has approved FASPRO (amivantamab and hyaluronidase), the first subcutaneous , for EGFR+ non small cell ( ), enabling five-minute administration with fewer infusion reactions. In Phase III PALOMA-3, subcutaneous delivery reduced administration-related reactions to 13% versus 66% with IV and improved survival when combined with . This approval builds on MARIPOSA data showing an overall survival benefit projected beyond four years.

The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated non small cell lung cancer (NSCLC), enabling five-minute administration with fewer infusion reactions. I

12/18/2025

The Phase 3 EV-304 KEYNOTE-B15 trial showed that perioperative vedotin ( ) plus ( ) significantly improved event-free survival and overall survival versus neoadjuvant and in cisplatin-eligible muscle-invasive . The platinum-free regimen also increased pathologic complete response rates, reinforcing its potential to redefine perioperative care across populations.
https://healthandpharma.net/padcev-keytruda-pembrolizumab-mi-bladder-cancer

12/17/2025

An international PANORAMA study shows that can outperform in detecting on routine . Across 3,440 patients, achieved an AUROC of 0.92 compared with 0.88 for 68 radiologists, detecting more while generating fewer false positive results. These findings underscore AI’s potential to support earlier of pancreatic ductal using standard-of-care imaging.
https://healthandpharma.net/ai-artificial-intelligence-detects-pancreatic-cancer-radiologists

12/17/2025

✅ The FDA has approved fam-trastuzumab deruxtecan-nxki ( ) plus pertuzumab for first-line treatment of unresectable or metastatic HER2+ , marking the first new option in this setting in over a decade. In the Phase III DESTINY-Breast09 trial, the regimen:
• Reduced the risk of progression or death by 44% vs THP
• Extended median PFS to 40.7 months vs 26.9 months
• Achieved a confirmed ORR of 87%
• Showed a safety profile consistent with known toxicities

These results establish Enhertu plus as a new benchmark for first-line HER2+ metastatic disease.
https://healthandpharma.net/fda-approves-enhertu-tdxd-pertuzumab-breast-cancer

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer, the first new option in over a decade. I

12/17/2025

has approved fam-trastuzumab deruxtecan-nxki ( ), in combination with (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2+ . The decision marks the first new first-line option in more than a decade for this patient population and reflects a meaningful advance in disease control for HER2-driven metastatic disease. In the Phase III DESTINY-Breast09 trial, the regimen reduced progression or death by 44%, extending median progression-free survival to 40.7 months versus 26.9 months with standard THP.

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer, the first new option in over a decade. I

12/16/2025

Lower-Dose Delivers Higher Responses and Longer Survival in ! Real-world data from nearly 400 patients with advanced, unresectable show that a flipped, lower-dose regimen increased objective response rates from 37% to 49%, tripled median progression-free survival from 3 to 9 months, and extended overall survival from 14 to 42 months, while reducing severe immune-related from 51% to 31%.

Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median progression-free survival from 3 to 9 months, and extended overall survival from 14 to 42 months,

12/14/2025

The Phase 3 MajesTEC 3 trial showed that plus reduced the risk of progression or death by 83% and achieved an 83.4 percent three year PFS rate in relapsed or refractory multiple , far surpassing standard regimens. The combination delivered markedly higher complete responses, deep MRD negativity, and an overall survival advantage, supporting a potential new second line standard.

The Phase 3 MajesTEC 3 trial showed that teclistamab plus daratumumab reduced the risk of progression or death by 83% and achieved an 83.4 percent three year PFS rate in relapsed or refractory multiple myeloma, far surpassing standard regimens.

12/13/2025

has approved ( and ) as the first precision therapy for BRCA2+ metastatic castration-sensitive ( ), following results from the Phase 3 AMPLITUDE trial showing a 54% reduction in radiographic progression or death and a 59% delay in symptomatic progression versus standard therapy. In + patients, median rPFS was not reached, underscoring the regimen’s strong -driven clinical benefit.

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE trial showing a 54% reduction in radiographic progression or death and a 59% delay

12/11/2025

GSK’s investigational antibody-drug conjugate (ADC) , also known as , has received Designation for the treatment of small-cell . The designation is anchored in early findings from the phase I ARTEMIS-001 study, where the B7-H3-targeted produced durable responses in patients with extensive-stage .
https://healthandpharma.net/gsk-adc-risvutatug-rezetecan-fda-orphan-drug-sclc

12/11/2025

New data presented by Novartis at highlight the durability of response achieved with , positioning the CDK4/6 inhibitor as a cornerstone therapy across metastatic and early HR+ HER2- . A pooled post hoc exploratory analysis from the MONALEESA program showed that one in four patients with HR+ HER2- advanced remained progression free for at least four years when treated with plus .

One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali plus endocrine therapy, according to pooled MONALEESA data presented at SABCS 2025.